Protalix BioTherapeutics (PLX) Cash from Investing Activities (2010 - 2026)
Protalix BioTherapeutics' (PLX) quarterly Cash from Investing Activities came in at $4.2 million in Q1 2026, up 1453.53% year-on-year from $271833.3 in Q1 2025, and up 479.77% quarter-over-quarter from -$1.1 million in Q4 2025.
Protalix BioTherapeutics (PLX) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 1453.53% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 51.96% decrease from a year earlier, with the FY2025 full-year figure at -$2.4 million, down 156.05% from the prior year.
- Cash from Investing Activities grew to $4.2 million in Q1 2026 per PLX's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $20.3 million in Q3 2024 and bottomed at -$20.9 million in Q3 2023.
- The 5-year median for Cash from Investing Activities is -$312000.0 (2025), against an average of -$921647.1.
- Across the five-year window, Cash from Investing Activities slumped 4379.53% in 2024 and soared 1453.53% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at $5.0 million in 2022, then tumbled by 106.9% to -$342000.0 in 2023, then slumped by 4379.53% to -$15.3 million in 2024, then soared by 92.74% to -$1.1 million in 2025, then soared by 479.77% to $4.2 million in 2026.
- Per Business Quant, the three latest PLX Cash from Investing Activities figures stand at $4.2 million (Q1 2026), -$1.1 million (Q4 2025), and -$504000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -45.51 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 178,242.27 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 172.62 Mn |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 4.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.22 Mn |
| Mar 31, 2026 | 4.22 Mn |
| Dec 31, 2025 | -1.11 Mn |
| Dec 31, 2025 | -1.11 Mn |
| Sep 30, 2025 | -504,000.00 |
| Sep 30, 2025 | -504,000.00 |
| Jun 30, 2025 | -438,000.00 |
| Jun 30, 2025 | -438,000.00 |
| Mar 31, 2025 | -312,000.00 |
| Mar 31, 2025 | -312,000.00 |
| Dec 31, 2024 | -15.32 Mn |
| Dec 31, 2024 | -15.32 Mn |
| Sep 30, 2024 | 20.33 Mn |
| Sep 30, 2024 | 20.33 Mn |
| Jun 30, 2024 | -180,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -606,000.00 |
| Mar 31, 2024 | -606,000.00 |
| Dec 31, 2023 | -342,000.00 |
| Dec 31, 2023 | -342,000.00 |